OPORF.US Open Orphan plc

Healthcare Biotechnology USA Stocks
0.0788 USD
Close of Nov 15, 2026
0.0788 0.2400
Market cap
USD 54.2M
P/E
-
P/B
1.27x
ROE
-80.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is OPORF.US undervalued?

Graham number

The Graham number of Open Orphan plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Open Orphan plc fundamental analysis

No fundamental analysis for Open Orphan plc yet.

Open Orphan plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Open Orphan plc

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immuno…

Full company profile